Navigation Links
MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results

- Conference Call to Begin Today at 9:00 a.m. ET -

VALENCIA, Calif., March 4 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and year ended December 31, 2007.

For the fourth quarter of 2007, total operating expenses were $79.1 million, compared to $71.8 million for the fourth quarter of 2006. Research and development (R&D) expenses increased by $7.0 million to $66.8 million for the fourth quarter of 2007 compared to the fourth quarter of 2006, primarily due to increased manufacturing costs (including clinical supplies) for Technosphere Insulin, offset in part by lower purchased services in the associated clinical development program. General and administrative (G&A) expenses increased by $0.3 million to $12.3 million for the fourth quarter of 2007 compared to the fourth quarter of 2006.

The net loss applicable to common stockholders for the fourth quarter of 2007 was $75.0 million, or $0.75 per share based on 99.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $71.3 million, or $1.30 per share based on 54.7 million weighted average shares outstanding, for the fourth quarter of 2006.

For the year ended December 31, 2007, total operating expenses were $307.4 million, compared with $233.8 million for 2006. R&D expenses were $256.8 million in 2007, up $65.0 million from 2006, primarily related to increases in manufacturing costs (including clinical supplies) for Technosphere Insulin and associated clinical development program expenses. G&A expenses increased by $8.5 million to $50.5 million for 2007 as compared to 2006 primarily due to costs associated with an increased number of employees and increased professional fees. The total number of employees increased from 545 at the end of 2006 to 609 at the end of 2007.

The net loss applicable to common stockholders for 2007 was $293.2 million, or $3.66 per share based on 80.0 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $230.5 million, or $4.52 per share based on 51.0 million weighted averages shares outstanding for 2006. The number of common shares outstanding at December 31, 2007 was 101,380,823.

Cash, cash equivalents and marketable securities were $368.3 million at December 31, 2007, $204.2 million at September 30, 2007, and $436.5 million at December 31, 2006. On October 5, 2007, the Company received $250 million in gross proceeds from its self managed registered direct offering of approximately 27 million shares of common stock.

"During this past year, we made excellent progress toward our goal of bringing Technosphere Insulin to market," stated Alfred Mann, Chairman and Chief Executive Officer. "It is clear that in today's environment, to be successful a new therapy must provide a differentiated safety and efficacy profile over existing therapies. We believe that Technosphere Insulin's unique ability to more closely match the normal pattern of insulin secretion following a meal will differentiate our product from other insulins, including rapid-acting analogs and long-acting analogs. Our Technosphere platform now includes MKC-253 (GLP-1), which in a recent Phase 1 trial demonstrated remarkable pharmacokinetics and a highly favorable safety profile. I am proud of what our team is accomplishing and I remain committed to seeing that these innovative products are made available to patients who desperately need improved therapeutic options."

Conference Call

MannKind management will host a conference call to discuss these results today at 9:00 a.m. ET. To participate in the call, please dial (888) 566-5775 or (210) 234-0004. To listen to the call via the internet, please visit The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (866) 396-7637 or (203) 369-0522.

Presenting from the Company will be:

-- Chairman and Chief Executive Officer Alfred Mann

-- President and Chief Operating Officer Hakan Edstrom

-- Corporate Vice President and Chief Financial Officer Dick Anderson

-- Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to differentiating Technosphere Insulin from other insulins. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations and involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2006 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

(Tables to follow)

MannKind Corporation

Consolidated Statements of Operations


(In thousands, except Three Months Ended Year Ended

per share amounts) December 31, December 31,

2007 2006 2007 2006

Revenue $- $- $10 $100

Operating expenses:

Research and

development 66,751 59,740 256,844 191,796

General and

administrative 12,316 12,058 50,523 42,001

Total operating

expenses 79,067 71,798 307,367 233,797

Loss from operations (79,067) (71,798) (307,357) (233,697)

Other (expense) /

income (355) 48 (197) 208

Interest expense on

note payable to

principal stockholder - (822) - (1,511)

Interest expense on

convertible debt (584) (222) (3,408) (222)

Interest income 4,996 1,526 17,775 4,679

Loss before provision

for income taxes (75,010) (71,268) (293,187) (230,543)

Income taxes (3) - (3) (5)

Net loss applicable to

common stockholders $(75,013) $(71,268) $(293,190) $(230,548)

Net loss per share

applicable to common

stockholders - basic

and diluted $(0.75) $(1.30) $(3.66) $(4.52)

Shares used to compute

basic and diluted net

loss per share

applicable to common

stockholders 99,605 54,684 80,038 50,970

MannKind Corporation

Condensed Balance Sheet


(in thousands)

December 31, December 31,

Assets 2007 2006

Current assets:

Cash and cash equivalents $368,285 $319,555

Marketable securities - 116,924

State research and development tax credit

exchange receivable -- current 831 2,418

Prepaid expenses and other current assets 9,596 10,650

Total current assets 378,712 449,547

Property and equipment -- net 162,683 88,328

State research and development tax credit

exchange receivable -- net of current

portion 1,500 1,500

Other assets 548 362

Total $543,443 $539,737

Liabilities and Stockholders' Equity

Current liabilities $67,558 $44,959

Other liabilities 24 24

Senior convertible notes 111,761 111,267

Stockholders' equity 364,100 383,487

Total $543,443 $539,737

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MannKind Corporation Reports Third Quarter Financial Results
2. MannKind to Present at Upcoming Conferences
3. MannKind Announces New $350 Million Credit Facility
4. Senior Lifestyle Corporation Names John Cobb as President and CEO
5. Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes
6. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
7. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
8. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
9. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
10. Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date
11. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since the start ... scientific research and discoveries, leading us to better understand the disease’s behavior. Globally, ... affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides insight on ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... amputations in the United States. Podiatrists are well aware that psychology-based patient non-compliance ... behaviors) are often catastrophic contributors to diseases of the diabetic foot. The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile imaging results ... subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are demonstrating new ... America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, at Booth ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... , Dec. 1, 2015  Today, ... the launch of CareFront, a first-of-its-kind population health ... diagnosed with cancer. Designed to be built into ... cancer patients with resources for their care and ... program also offers tools to help patients understand ...
Breaking Medicine Technology: